Intracellular Peptide Cross-linking for PPI Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing conformationally constrained peptides to inhibit intracellular protein-protein interactions are inefficient, as they require chemical modification outside the cell followed by intracellular introduction, making it difficult to predict peptide tolerance and activity.
Innovation Solution
A method where a recombinant peptide with derivatizable amino acid residues is expressed within a cell and then cross-linked using a suitable cross-linker, allowing for the production and intracellular screening of conformationally constrained peptides in a single process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chemical modification is performed outside the cell to produce conformationally constrained peptides, then the peptide conformation can be precisely controlled, but the process complexity and time required for intracellular screening increase significantly
Solution Approach 1:
The patent combines the peptide expression and cross-linking steps into a single intracellular process. The recombinant peptide is expressed within the cell and then cross-linked in situ using membrane-permeable cross-linking reagents, eliminating the need for separate in vitro chemical modification and intracellular introduction steps. This merging of steps reduces process complexity while maintaining conformational control.
Solution Approach 2:
The cell itself serves as the reaction vessel for peptide synthesis and cross-linking. The intracellular environment provides the necessary conditions for peptide expression and modification, and the cell can immediately be used for screening assays. This self-service approach eliminates the need for external processing equipment and multiple transfer steps.
2Manufacturing precision
If chemical modification is performed outside the cell, then conformational constraint can be achieved, but the time required for peptide production and screening increases
Solution Approach 1:
The patent enables continuous processing where peptide expression and cross-linking occur sequentially within the same cell without interruption. The cell is transformed with the peptide encoding sequence, expresses the recombinant peptide, and then undergoes cross-linking all within the same culture period. This continuous action eliminates the time losses associated with harvesting, purifying, and reintroducing peptides into cells.
Solution Approach 2:
The peptide is expressed and prepared for cross-linking within the cell before any screening assays are performed. This preliminary preparation ensures that the conformationally constrained peptide is already in place and ready for immediate functional testing, eliminating delays between production and screening.
3Manufacturing precision
If peptide cross-linking is performed in vitro, then the cross-linking conditions can be precisely controlled, but the ability to predict intracellular peptide activity is reduced
Solution Approach 1:
The patent changes the location parameter from in vitro to in vivo, performing cross-linking within the cell where the physiological conditions (pH, ionic strength, molecular chaperones) naturally exist. This ensures that the cross-linked peptide adopts the correct conformation for intracellular function. The cross-linking reagents are selected to be membrane-permeable and to work under physiological conditions, maintaining precision while improving reliability of intracellular activity prediction.
4Manufacturing precision
If multiple steps are used for peptide production and screening, then each step can be optimized independently, but the overall process efficiency decreases
Solution Approach 1:
The patent merges peptide expression, cross-linking, and screening into a unified intracellular workflow. The cell serves as both the production factory and the testing environment, allowing simultaneous optimization of all parameters within a single system. This eliminates the inefficiencies of multiple independent optimization cycles and inter-step transfers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient production and screening of conformationally constrained peptides within cells, simplifying the identification of peptide inhibitors for intracellular protein-protein interactions and enhancing their ability to disrupt these interactions.
Implementation Method 1
contacting the cell with a cross-linker, wherein the cross-linker is capable of reacting with said reactive thiol groups; and culturing the cell in the presence of the cross-linker, such that the cross-linker forms thioether cross-links with the at least two derivatisable amino acids
Data Source
AI summary
Disclosed are methods and kits for producing a conformationally constrained peptide, such as a helix constrained peptide, in a cell. In some cases, the methods comprise contacting a cell comprising an intracellularly-localised recombinant peptide with a cross-linker and culturing the cell in the presence of the cross-linker, wherein the cross-linker forms thioether cross-links with at least two derivatisable amino acids located at anchoring positions in the recombinant peptide. The methods and kits and cells find application, for example, in the identification of inhibitors that can be used to disrupt protein-protein interactions.